978.F ADAGENE INC. SP.ADR
- Market cap
- EUR 120M
- P/E
- -
- P/B
- 1.46x
- ROE
- -49.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 978.F undervalued?
Graham numberThe Graham number of ADAGENE INC. SP.ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ADAGENE INC. SP.ADR fundamental analysis
No fundamental analysis for ADAGENE INC. SP.ADR yet.
ADAGENE INC. SP.ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ADAGENE INC. SP.ADR
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials …
Full company profileADAGENE INC. SP.ADR financial statements
ADAGENE INC. SP.ADR annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 10.2M | 9.29M | 18.1M | 103K | 7.67M |
| Operating Income | -72.4M | -83.9M | -23.7M | -36.0M | -21.4M |
| EBITDA | - | -77.4M | -14.9M | -31.7M | -16.9M |
| Net Income | -73.2M | -80.0M | -18.9M | -33.4M | -17.6M |
| EPS | -1.34 | -1.48 | -0.34 | -0.57 | -0.30 |
| Balance Sheet | |||||
| Total Assets | 190M | 152M | 116M | 89.3M | 78.3M |
| Total Liabilities | 33.0M | 69.3M | 45.2M | 38.7M | 42.9M |
| Shareholders' Equity | 157M | 83.1M | 70.6M | 50.5M | 35.3M |
| Cash & Short-term Investments | 174M | 144M | 110M | 85.2M | 74.5M |
| Cash Flow | |||||
| Operating Cash Flow | -43.4M | -48.6M | -28.5M | -29.7M | -15.7M |
| Capital Expenditure | 2.51M | 691K | 85.0K | 33.6K | 17.1K |
| Free Cash Flow | -45.9M | -49.3M | -28.5M | -29.7M | -15.7M |
| Ratios | |||||
| ROE | -46.7% | -96.2% | -26.9% | -66.2% | -49.8% |
| ROA | -38.6% | -52.5% | -16.4% | -37.4% | -22.5% |
| Net Profit Margin | -719.2% | -860.6% | -104.6% | -32,386.4% | -229.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ADAGENE INC. SP.ADR dividends
ADAGENE INC. SP.ADR has not paid dividends in the last 5 fiscal years.
Who owns ADAGENE INC. SP.ADR
- Insiders 11.40%
- Institutions 36.06%
- Public & others 52.54%
- Shares outstanding 67.1M
- Free float 44.8M
ADAGENE INC. SP.ADR company profile
- Company name
- ADAGENE INC. SP.ADR
- Ticker
- 978.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 128
- Fiscal year end
- December
- Address
- Building C14, Suzhou, China, 215123
- Phone
- 86 512 8777 3632
- Website
- adagene.com
About ADAGENE INC. SP.ADR
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
ADAGENE INC. SP.ADR management
10- Dr. Peter P. Luo Ph.D.Co- Founder, Chairman, CEO and President of R&D · born 1966
- Mr. Man Kin Tam M.B.A.CFO & Director · born 1977
- Ms. Ling ZhouExecutive Director & Head of Human Resources
- Dr. Qinghai Zhao Ph.D.Chief Manufacturing Officer · born 1961
- Mr. Mickael Chane-DuChief Strategy Officer
- Ms. Yan Li M.B.A.Senior Vice President of Bioinformatics & Information Technology · born 1975
- Ms. Xiaohong SheSenior VP & Head of Clinical Operations · born 1967
- Dr. Guizhong Liu Ph.D.Senior Vice President of Early Drug Discovery · born 1971
- Mr. Alexander GoergenVP & Head of Business Development · born 1987
- Dr. Jiping Zha M.D., Ph.D.Executive Vice President of Clinical Development